ema prac naion semaglutide june 2025 A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. https://www.medpagetoday.com/ophthalmology/generalophthalmology/115938?trw=no Eye Condition a 'Very Rare'

Doctors weigh health factors like comorbidities and whether the patient will commit to continuous monitoring, lifestyle changes, and an injection regimen

conducted a systematic review and meta-analysis involving 37 RCTs and 19 real-world studies to assess the safety of semaglutide [132]

Diet versions are marginally better but still have poor mineral profiles

Oral semaglutide is not addictive or habit-forming

Our team can help you determine whether your plan covers your weight loss treatment

Solid Timestamps Fix Context This level of detail turns anecdotes into a timeline clinicians can use, and it reduces the frustrating back-and-forth that often leaves patients feeling dismissed